Sez. 1 - Gestione delle cisti epatiche e delle loro complicanze · GIN - Anno 33 - Vol. 5

Home > Linee Guida per la Malattia Policistica Renale dell'Adulto

Pubblicato il 4 ottobre 2016

Sez. 1 - Gestione delle cisti epatiche e delle loro complicanze

Sezione 1: Gestione delle cisti epatiche e delle loro complicanze

Giovanni Piscopo¹, Giovanna Capolongo²

(1) UOC Nefrologia, dialisi e trapianto - Dipartimento emergenze e trapianti di organo AOU Policlinico Di Bari
(2) UOC Nefrologia e Dialisi - AOU Seconda Università degli Studi di Napoli

Corrispondenza a:
Giovanni Piscopo; UOC Nefrologia, dialisi e trapianto - Dipartimento emergenze e trapianti di organo AOU Policlinico Di Bari, Piazzale Giulio Cesare 11 - 70124 Bari; E-mail: giopiscopo@gmail.com
Giovanna Capolongo; UOC Nefrologia e Dialisi - AOU Seconda Università degli Studi di Napoli, Edif 17 via Pansini 5 - 80131 Napoli ; Tel: +39 081 56 66 666 ; Fax: +39 081 56 66 666 ; E-mail: giovi.capolongo@gmail.com

Abstract

Indice delle sezioni

SEZIONE 1: Gestione delle cisti epatiche e delle loro complicanze
SEZIONE 2: Gestione delle cisti pancreatiche e delle loro complicanze
SEZIONE 3: Gestione dei diverticoli intestinali e delle loro complicanze
SEZIONE 4: Gestione delle ernie addominali
SEZIONE 5: Gestione dell’ipertensione arteriosa nei pazienti affetti da ADPKD
SEZIONE 6: Gestione e trattamento delle infezioni delle cisti renali nei pazienti ADPKD
SEZIONE 7: Nefrolitiasi
SEZIONE 8: Gestione del paziente ADPKD con ematuria
SEZIONE 9: Carcinoma renale
SEZIONE 10: Aneurismi intracranici

BibliografiaReferences

[1] Gevers TJ, Drenth JP Diagnosis and management of polycystic liver disease. Nature reviews. Gastroenterology & hepatology 2013 Feb;10(2):101-8

[2] Cnossen WR, Drenth JP Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management. Orphanet journal of rare diseases 2014 May 1;9:69 (full text)

[3] Chandok N Polycystic liver disease: a clinical review. Annals of hepatology 2012 Nov-Dec;11(6):819-26 (full text)

[4] van Keimpema L, Nevens F, Vanslembrouck R et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009 Nov;137(5):1661-8.e1-2

[5] Caroli A, Antiga L, Cafaro M et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clinical journal of the American Society of Nephrology : CJASN 2010 May;5(5):783-9 (full text)

[6] Everson GT, Scherzinger A, Berger-Leff N et al. Polycystic liver disease: quantitation of parenchymal and cyst volumes from computed tomography images and clinical correlates of hepatic cysts. Hepatology (Baltimore, Md.) 1988 Nov-Dec;8(6):1627-34

[7] Nicolau C, Torra R, Bianchi L et al. Abdominal sonographic study of autosomal dominant polycystic kidney disease. Journal of clinical ultrasound : JCU 2000 Jul-Aug;28(6):277-82

[8] Levine E, Cook LT, Grantham JJ et al. Liver cysts in autosomal-dominant polycystic kidney disease: clinical and computed tomographic study. AJR. American journal of roentgenology 1985 Aug;145(2):229-33

[9] Bae KT, Zhu F, Chapman AB et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clinical journal of the American Society of Nephrology : CJASN 2006 Jan;1(1):64-9 (full text)

[10] Wijnands TF, Neijenhuis MK, Kievit W et al. Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Liver international : official journal of the International Association for the Study of the Liver 2014 Nov;34(10):1578-83

[11] Masoumi A, Reed-Gitomer B, Kelleher C et al. Developments in the management of autosomal dominant polycystic kidney disease. Therapeutics and clinical risk management 2008 Apr;4(2):393-407 (full text)

[12] Temmerman F, Dobbels F, Ho TA et al. Development and validation of a polycystic liver disease complaint-specific assessment (POLCA). Journal of hepatology 2014 Nov;61(5):1143-50

[13] Waanders E, van Keimpema L, Brouwer JT et al. Carbohydrate antigen 19-9 is extremely elevated in polycystic liver disease. Liver international : official journal of the International Association for the Study of the Liver 2009 Oct;29(9):1389-95

[14] Deschênes M, Michel RP, Alpert E et al. Elevation of CA-125 level is due to abdominal distension in liver transplantation candidates. Transplantation 2001 Nov 15;72(9):1519-22

[15] Iwase K, Takenaka H, Oshima S et al. Determination of tumor marker levels in cystic fluid of benign liver cysts. Digestive diseases and sciences 1992 Nov;37(11):1648-54

[16] van Erpecum KJ, Janssens AR, Terpstra JL et al. Highly symptomatic adult polycystic disease of the liver. A report of fifteen cases. Journal of hepatology 1987 Aug;5(1):109-17

[17] Que F, Nagorney DM, Gross JB Jr et al. Liver resection and cyst fenestration in the treatment of severe polycystic liver disease. Gastroenterology 1995 Feb;108(2):487-94

[18] Kabbej M, Sauvanet A, Chauveau D et al. Laparoscopic fenestration in polycystic liver disease. The British journal of surgery 1996 Dec;83(12):1697-701

[19] Abu-Wasel B, Walsh C, Keough V et al. Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases. World journal of gastroenterology 2013 Sep 21;19(35):5775-86 (full text)

[20] Hoevenaren IA, Wester R, Schrier RW et al. Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver international : official journal of the International Association for the Study of the Liver 2008 Feb;28(2):264-70

[21] Sherstha R, McKinley C, Russ P et al. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology (Baltimore, Md.) 1997 Nov;26(5):1282-6

[22] Alvaro D, Mancino MG, Onori P et al. Estrogens and the pathophysiology of the biliary tree. World journal of gastroenterology 2006 Jun 14;12(22):3537-45 (full text)

[23] Rosenfeld L, Bonny C, Kallita M et al. [Polycystic liver disease and its main complications]. Gastroenterologie clinique et biologique 2002 Dec;26(12):1097-106 (full text)

[24] Arnold HL, Harrison SA New advances in evaluation and management of patients with polycystic liver disease. The American journal of gastroenterology 2005 Nov;100(11):2569-82

[25] Marion Y, Brevartt C, Plard L et al. Hemorrhagic liver cyst rupture: an unusual life-threatening complication of hepatic cyst and literature review. Annals of hepatology 2013 Mar-Apr;12(2):336-9 (full text)

[26] Chauveau D, Fakhouri F, Grünfeld JP et al. Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma. Journal of the American Society of Nephrology : JASN 2000 Sep;11(9):1767-75 (full text)

[27] Alvaro D, Gigliozzi A, Attili AF et al. Regulation and deregulation of cholangiocyte proliferation. Journal of hepatology 2000 Aug;33(2):333-40

[28] Møller LN, Stidsen CE, Hartmann B et al. Somatostatin receptors. Biochimica et biophysica acta 2003 Sep 22;1616(1):1-84 (full text)

[29] Tan CK, Podila PV, Taylor JE et al. Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition. Gastroenterology 1995 Jun;108(6):1908-16

[30] Pyronnet S, Bousquet C, Najib S et al. Antitumor effects of somatostatin. Molecular and cellular endocrinology 2008 May 14;286(1-2):230-7

[31] Gevers TJ, Chrispijn M, Wetzels JF et al. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease. BMC nephrology 2012 Apr 4;13:17 (full text)

[32] Chrispijn M, Nevens F, Gevers TJ et al. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Alimentary pharmacology & therapeutics 2012 Jan;35(2):266-74 (full text)

[33] Gevers TJ, Hol JC, Monshouwer R et al. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial. Liver international : official journal of the International Association for the Study of the Liver 2015 May;35(5):1607-14

[34] Meijer E, Drenth JP, d'Agnolo H et al. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. American journal of kidney diseases : the official journal of the National Kidney Foundation 2014 Mar;63(3):446-55

[35] Caroli A, Perico N, Perna A et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet (London, England) 2013 Nov 2;382(9903):1485-95

[36] Hogan MC, Masyuk TV, Page LJ et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. Journal of the American Society of Nephrology : JASN 2010 Jun;21(6):1052-61 (full text)

[37] Hogan MC, Masyuk TV, Page L et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2012 Sep;27(9):3532-9 (full text)

[38] Pisani A, Sabbatini M, Imbriaco M et al. Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2016 Jul;14(7):1022-1030.e4

[39] Gevers TJ, Inthout J, Caroli A et al. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology 2013 Aug;145(2):357-65.e1-2

[40] Qian Q, Du H, King BF et al. Sirolimus reduces polycystic liver volume in ADPKD patients. Journal of the American Society of Nephrology : JASN 2008 Mar;19(3):631-8 (full text)

[41] Ruggenenti P, Gentile G, Perico N et al. Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. Clinical journal of the American Society of Nephrology : CJASN 2016 May 6;11(5):785-94

[42] Park, Jang. Sirolimus for ADPKD paients with massive Polycystic Liver (SILVER): an interim analysis. NDT Volume 29, Issue suppl 3, PP III5-III6 (S0015)

[43] Chrispijn M, Gevers TJ, Hol JC et al. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. Journal of hepatology 2013 Jul;59(1):153-9

[44] Drenth JP, Chrispijn M, Nagorney DM et al. Medical and surgical treatment options for polycystic liver disease. Hepatology (Baltimore, Md.) 2010 Dec;52(6):2223-30

[45] Saini S, Mueller PR, Ferrucci JT Jr et al. Percutaneous aspiration of hepatic cysts does not provide definitive therapy. AJR. American journal of roentgenology 1983 Sep;141(3):559-60

[46] Bean WJ, Rodan BA Hepatic cysts: treatment with alcohol. AJR. American journal of roentgenology 1985 Feb;144(2):237-41

[47] van Keimpema L, de Koning DB, Strijk SP et al. Aspiration-sclerotherapy results in effective control of liver volume in patients with liver cysts. Digestive diseases and sciences 2008 Aug;53(8):2251-7

[48] Kairaluoma MI, Leinonen A, Ståhlberg M et al. Percutaneous aspiration and alcohol sclerotherapy for symptomatic hepatic cysts. An alternative to surgical intervention. Annals of surgery 1989 Aug;210(2):208-15

[49] Takei R, Ubara Y, Hoshino J et al. Percutaneous transcatheter hepatic artery embolization for liver cysts in autosomal dominant polycystic kidney disease. American journal of kidney diseases : the official journal of the National Kidney Foundation 2007 Jun;49(6):744-52

[50] Park HC, Kim CW, Ro H et al. Transcatheter arterial embolization therapy for a massive polycystic liver in autosomal dominant polycystic kidney disease patients. Journal of Korean medical science 2009 Feb;24(1):57-61 (full text)

[51] Wang MQ, Duan F, Liu FY et al. Treatment of symptomatic polycystic liver disease: transcatheter super-selective hepatic arterial embolization using a mixture of NBCA and iodized oil. Abdominal imaging 2013 Jun;38(3):465-73

[52] Garcea G, Rajesh A, Dennison AR et al. Surgical management of cystic lesions in the liver. ANZ journal of surgery 2013 Jul;83(7-8):E3-E20

[53] Russell RT, Pinson CW Surgical management of polycystic liver disease. World journal of gastroenterology 2007 Oct 14;13(38):5052-9 (full text)

[54] van Keimpema L, Drenth JP Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Annals of surgery 2011 Feb;253(2):419; author reply 420

[55] Armitage NC, Blumgart LH Partial resection and fenestration in the treatment of polycystic liver disease. The British journal of surgery 1984 Mar;71(3):242-4

[56] Schindl MJ, Redhead DN, Fearon KC et al. The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection. Gut 2005 Feb;54(2):289-96 (full text)

[57] Gigot JF, Jadoul P, Que F et al. Adult polycystic liver disease: is fenestration the most adequate operation for long-term management? Annals of surgery 1997 Mar;225(3):286-94

[58] Kirchner GI, Rifai K, Cantz T et al. Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2006 Aug;12(8):1268-77 (full text)

[59] Everson GT, Taylor MR, Doctor RB et al. Polycystic disease of the liver. Hepatology (Baltimore, Md.) 2004 Oct;40(4):774-82

[60] Pirenne J, Aerts R, Yoong K et al. Liver transplantation for polycystic liver disease. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2001 Mar;7(3):238-45 (full text)

[61] Saidi RF, Jabbour N, Shah SA et al. Improving Outcomes of Liver Transplantation for Polycystic Disease in MELD Era. International journal of organ transplantation medicine 2013;4(1):27-9

[62] Arrazola L, Moonka D, Gish RG et al. Model for end-stage liver disease (MELD) exception for polycystic liver disease. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2006 Dec;12(12 Suppl 3):S110-1 (full text)

[63] Freeman RB Jr, Gish RG, Harper A et al. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2006 Dec;12(12 Suppl 3):S128-36 (full text)

[64] Schnelldorfer T, Torres VE, Zakaria S et al. Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Annals of surgery 2009 Jul;250(1):112-8

[65] Grünfeld JP, Albouze G, Jungers P et al. Liver changes and complications in adult polycystic kidney disease. Advances in nephrology from the Necker Hospital 1985;14:1-20

[66] Torres VE Polycystic liver disease. Contributions to nephrology 1995;115:44-52

[67] McDonald MI, Corey GR, Gallis HA et al. Single and multiple pyogenic liver abscesses. Natural history, diagnosis and treatment, with emphasis on percutaneous drainage. Medicine 1984 Sep;63(5):291-302

[68] Telenti A, Torres VE, Gross JB Jr et al. Hepatic cyst infection in autosomal dominant polycystic kidney disease. Mayo Clinic proceedings 1990 Jul;65(7):933-42

[69] Chauveau D, Pirson Y, Le Moine A et al. Extrarenal manifestations in autosomal dominant polycystic kidney disease. Advances in nephrology from the Necker Hospital 1997;26:265-89

[70] Sallée M, Rafat C, Zahar JR et al. Cyst infections in patients with autosomal dominant polycystic kidney disease. Clinical journal of the American Society of Nephrology : CJASN 2009 Jul;4(7):1183-9 (full text)

[71] Lantinga MA, Gevers TJ, Drenth JP et al. Evaluation of hepatic cystic lesions. World journal of gastroenterology 2013 Jun 21;19(23):3543-54 (full text)

[72] Balbo BE, Sapienza MT, Ono CR et al. Cyst infection in hospital-admitted autosomal dominant polycystic kidney disease patients is predominantly multifocal and associated with kidney and liver volume. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.] 2014 Jul;47(7):584-93 (full text)

[73] Akriviadis EA, Steindel H, Ralls P, Redeker AG. Spontaneous rupture of nonparasitic cyst of the liver. Gastroenterology. 1989 Jul [cited 2015 Mar 2];97(1):213–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2721870

[74] O'Brien K, Font-Montgomery E, Lukose L et al. Congenital hepatic fibrosis and portal hypertension in autosomal dominant polycystic kidney disease. Journal of pediatric gastroenterology and nutrition 2012 Jan;54(1):83-9

[75] Shorbagi A, Bayraktar Y Experience of a single center with congenital hepatic fibrosis: a review of the literature. World journal of gastroenterology 2010 Feb 14;16(6):683-90 (full text)

[76] Manuscript A. NIH Public Access. Am J Med Genet Part C Semin Med Genet. 2010.

[77] Kummer S, Sagir A, Pandey S et al. Liver fibrosis in recessive multicystic kidney diseases: transient elastography for early detection. Pediatric nephrology (Berlin, Germany) 2011 May;26(5):725-31

Per visualizzare l'intero documento devi essere registrato e aver eseguito la login con utente e password.

Scarica l’APP del GIN per il tuo smartphone o tablet:

Versione PDF

 PDF

Per visualizzare l'intero documento devi essere registrato e aver eseguito la login con utente e password.

Contenuti articolo

release 1
pubblicata il 04 ottobre 2016
Da

Giovanni Piscopo¹, Giovanna Capolongo²

(1) UOC Nefrologia, dialisi e trapianto - Dipartimento emergenze e trapianti di organo AOU Policlinico Di Bari
(2) UOC Nefrologia e Dialisi - AOU Seconda Università degli Studi di Napoli

Parole chiave: __fit__

Non ci sono commenti

	Tipo A	Tipo B	Tipo C	Tipo D
Sintomi	Assenti o lievi	Moderati o severi	Severi o moderati	Severi o moderati
Caratteristiche delle cisti	Qualunque	N° limitato di cisti	Qualunque	Qualunque
Aree di parenchima normale	Qualunque	≥2 settori	≥1 settore	<1 settore
Occlusione della vena epatica o della vena porta di settori preservati	Qualunque	Assenti	Assente	Presente

Login